RecruitingPhase 2Phase 3NCT05753267

Fenofibrate in Ulcerative Colitis

Clinical Study to Evaluate the Possible Efficacy of Fenofibrate in Patient With Ulcerative Colitis

Sponsor

Tanta University

Enrollment

60 participants

Start Date

Feb 28, 2023

Study Type

INTERVENTIONAL

Conditions

Inflammatory Bowel Diseases

Summary

Fibrates, which are specific pharmacological agonists of PPARα, have been widely used in the treatment of hypercholesterolemia and hypertriglyceridemia. Apart from their metabolic action, anti-inflammatory properties of fibrates have been described, including inhibition of NF-kappa B signaling and pro-inflammatory cytokine production. 4 Fenofibrate, an important peroxisome proliferator-activated receptor-a (PPAR- α) agonist, is widely used in clinical as a triglyceride (TG)-lowering agent.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether fenofibrate, a cholesterol-lowering medication, can reduce inflammation and improve symptoms in people with mild to moderate ulcerative colitis (UC), an inflammatory bowel disease that causes colon inflammation. **You may be eligible if...** - You are 18 or older - You have been diagnosed with mild or moderate ulcerative colitis confirmed by colonoscopy - You are not pregnant and are using effective contraception (if applicable) **You may NOT be eligible if...** - You are breastfeeding - You have significant liver or kidney disease - You have colorectal cancer - You have Crohn's disease or other inflammatory bowel diseases - You have severe UC - You are currently taking steroids, immunosuppressants, or biological therapies Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMesalamine

Mesalamine (also known as mesalamine or 5- amino salicylic acid, 5-ASA) has a well-established role in UC management. It is the first line therapy for mild to moderate UC and it is considered the cornerstone in the management of UC

DRUGFenofibrate 160mg

Fibrates, which are specific pharmacological agonists of PPARα, have been widely used in the treatment of hypercholesterolemia and hypertriglyceridemia.